Dragonfly Therapeutics

Dragonfly Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, focused on developing innovative therapeutics that activate immune responses against cancer. Utilizing its TriNKET platform, the company creates first-in-class drugs that target natural killer cells and other components of the innate immune system, effectively addressing immune suppressive factors within the tumor microenvironment. These novel therapies aim to enhance anti-cancer immune responses both as standalone treatments and in combination with existing cancer immunotherapies. Founded in 2015, Dragonfly Therapeutics collaborates strategically with major pharmaceutical companies, including Celgene Corporation and Merck, to advance its research and development efforts. The company's scientific founders are recognized leaders in cancer biology and immunology, driving its mission to harness the immune system's potential for breakthrough cancer treatments.